MTEX earnings analysis
What we found in MTEX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so current-quarter revenue, margins, EPS, cash flow, and year-over-year trends cannot be quantified. The most material disclosed development is the April 20, 2026 Nasdaq notice regarding the $2,500,000 minimum-equity requirement. Management reported effective disclosure controls as of June 30, 2026, but provided no quantitative forward guidance in the supplied filing text.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported 0 material changes to internal control over financial reporting during the quarter.
- Limited financial-instrument exposure
- The filing states that the company has not issued any debt instruments and has not entered into forward, futures, option, or swap agreements, limiting disclosed exposure to certain financial market risks.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq minimum-equity deficiency
- The company disclosed that it received an April 20, 2026 Nasdaq notice for noncompliance with Listing Rule 5550(b)(1), which requires at least $2,500,000 of stockholders’ equity. Failure to regain compliance could result in delisting and impair access to capital.
- Tariff and trade-policy exposure
- The filing adds or expands discussion of trade-policy risk involving the United States, Mexico, Canada, China, South Korea, and other countries. Tariffs, retaliation, or export restrictions could increase costs, disrupt shipments, and pressure profitability, with no quantified mitigation benefit provided.
- Unhedged currency volatility
- The company remains exposed to foreign-currency fluctuations because it translates international revenue and expenses at average exchange rates and does not use financial instruments to hedge that exposure. The filing states that future effects on results and cash flows cannot be predicted with certainty.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; outlook may be deferred to the earnings release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Mannatech, Inc. reported a decrease in revenue and a net loss in Q1 2026 compared to Q1 2025, with revenue of $24.9 million, down 6.2% year-over-year, and a net income of $1.0 million, improving from a net loss of $1.5…
- 10-K · April 15, 2026
- Mannatech positions itself as a network-marketing focused nutritional supplements company selling proprietary glyconutrient products (notably Ambrotose®, developed and patented in 1996) across three regions (Americas,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MTEX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever